Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Prolonged exposure to silica dust, a common mineral found in materials like kitchen countertops, can lead to silicosis, a ...

Idiopathic pulmonary fibrosis (IPF) is a fatal disease that's all the more difficult ... Nothing changed and an equally inconclusive chest X-ray was followed by a CT scan, which resulted in ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

Obstructive lung diseases like asthma and chronic obstructive pulmonary disorder (COPD) cause more trouble when you’re exhaling air. Restrictive lung diseases such as pulmonary fibrosis make ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

The conditions commonly considered as ILDs include various disorders such as idiopathic pulmonary fibrosis (IPF), connective tissue disease-ILD (CTD-ILD), chronic hypersensitivity pneumonitis, and ...